See What HealthDay Can Do For You
Contact Us

Asthma Not Common in COVID-19 Patients Who Have Died

Only about 5 percent of COVID-19 patients in New York State who have died had asthma

asthma inhaler

FRIDAY, April 17, 2020 (HealthDay News) -- Asthma is not among the top 10 chronic health problems in people who have died from coronavirus disease 2019 (COVID-19) in New York state, even though many health experts have warned that people with asthma are at increased risk for severe illness if they get COVID-19.

Data released this month by New York state, the epicenter of the U.S. outbreak, show that only about 5 percent of COVID-19 patients who have died had asthma, The New York Times reported. The state said the top 10 comorbid health conditions in COVID-19 patients who have died are: high blood pressure, diabetes, high cholesterol, coronary heart disease, dementia, atrial fibrillation, chronic obstructive pulmonary disease, kidney disease, cancer, and congestive heart failure.

"We're not seeing a lot of patients with asthma," Bushra Mina, M.D., a pulmonary and critical care physician at Lenox Hill Hospital in New York City, told The Times. The hospital has treated more than 800 COVID-19 cases. The more common risk factors among COVID-19 patients have been "morbid obesity, diabetes, and chronic heart disease," Mina added.

There is little research on the association between asthma and COVID-19 at the moment, and the findings are not consistent. It is "striking" that asthma appeared "to be underrepresented in the comorbidities reported for patients with COVID-19," a group of European researchers wrote in a recent commentary in The Lancet, The Times reported.

The New York Times Article

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.